Chromosome abnormalities in ovarian adenocarcinoma: I. nonrandom chromosome abnormalities from 244 cases

Cytogenetics provides important insights into the molecular pathogenesis of human cancers. Although extensive data exist on recurring cytogenetic abnormalities in hematologic cancers, data on individual solid tumor types remain limited. Previous studies of ovarian carcinoma indicated the presence of multiple, complex clonal chromosome abnormalities. Cytogenetics remains one of a few techniques capable of detecting these multiple, simultaneously occurring genetic abnormalities. We describe cytogenetic abnormalities from a series of 244 primary ovarian cancer specimens referred to a single institution. A total of 201/244 cases had fully characterized clonal chromosome abnormalities, of which 134 showed clonal chromosome breakpoints. We used a novel statistical technique to detect nonrandom chromosome breakpoints at the level of chromosome regions. Nonrandom occurrence of chromosome breakpoints was detected at regions 1p1*, 1q1*, 1p2*, 1q2*, 1p3*, 1q3, 3p1*, 1q4*, 6q1*, 6p2, 6q2, 7p1*, 7q1, 7p2*, 11p1*, 11q1, 11q2*, 12p1, 12q2*, 13p1, and 19q1. Simultaneous occurrence of multiple abnormalities was common. However, 120/134 cases had breakpoints at one or more of 13 commonly involved regions (*), suggesting a hierarchy of genetic abnormalities. Among clinical and tumor variables that predict patient survival, tumor grade was significantly associated with the presence of chromosome breakpoints. In additional studies, we show that nonrandom chromosome abnormalities are associated with impaired survival in ovarian cancer and that specific, nonrandomly involved chromosome regions retain significant effects on survival when analyses are controlled for important clinical variables. Additional specific chromosome abnormalities in this series are described, including chromosome gains and losses in near‐diploid cases and homogeneously staining regions. These results suggest that recurring, nonrandom chromosome abnormalities are important in the pathogenesis and/or progression of ovarian cancers, and target areas of the genome for molecular genetic studies. Genes Chromosomes Cancer 25:290–300, 1999. © 1999 Wiley‐Liss, Inc.

[1]  F. Mitelman,et al.  Karyotypic characteristics of borderline malignant tumors of the ovary: trisomy 12, trisomy 7, and r(1) as nonrandom features. , 1996, Cancer genetics and cytogenetics.

[2]  A. Retief,et al.  Chromosome changes in 17 human neoplasms studied with banding , 1979, Cancer.

[3]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[4]  P. Russell Surgical pathology of ovaries , 1990 .

[5]  B Johansson,et al.  Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. , 1997, Cancer research.

[6]  Aimo Ojala Studies on Bilirubin in Amniotic Fluid: With Special Reference to Liver Function Tests , 1971, Acta obstetricia et gynecologica Scandinavica. Supplement.

[7]  J. Rowley,et al.  The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. , 1994, Blood.

[8]  M. Aickin,et al.  Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. , 1996, American journal of public health.

[9]  S. Holm A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[10]  N. Wake,et al.  Specific cytogenetic changes in ovarian cancer involving chromosomes 6 and 14. , 1980, Cancer research.

[11]  D. Pinkel,et al.  Genetic analysis of benign, low-grade, and high-grade ovarian tumors. , 1995, Cancer research.

[12]  M. Tattersall,et al.  Cytogenetic study of solid ovarian tumors. , 1990, Cancer genetics and cytogenetics.

[13]  L. Hartmann,et al.  Cytogenetic studies of epithelial ovarian carcinoma. , 1993, Cancer genetics and cytogenetics.

[14]  P. Nowell Cytogenetic approaches to human cancer genes 1 , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  J. Trent,et al.  Clonal chromosome abnormalities in human breast carcinomas I. Twenty‐eight cases with primary disease , 1993, Genes, chromosomes & cancer.

[16]  D. Powell,et al.  Chromosome abnormalities in human epithelial ovarian malignancies , 1990, Gynecologic oncology.

[17]  D. Alberts,et al.  Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies. , 1996, Cancer genetics and cytogenetics.

[18]  D. Sheer,et al.  Clinical applications of genetic rearrangements in cancer. , 1996, Seminars in cancer biology.

[19]  B. Johansson,et al.  A breakpoint map of recurrent chromosomal rearrangements in human neoplasia , 1997, Nature Genetics.

[20]  F. Mitelman,et al.  Chromosome aberrations in 35 primary ovarian carcinomas , 1992, Genes, chromosomes & cancer.

[21]  B. Johansson,et al.  Primary vs. secondary neoplasia‐associated chromosomal abnormalities—balanced rearrangements vs. genomic imbalances? , 1996, Genes, chromosomes & cancer.

[22]  B. Johansson,et al.  Isochromosomes in neoplasia , 1994, Genes, chromosomes & cancer.

[23]  D. Ledbetter,et al.  Multicolor Spectral Karyotyping of Human Chromosomes , 1996, Science.

[24]  F. Mitelman,et al.  Prognostic impact of chromosome aberrations in ovarian cancer. , 1992, British Journal of Cancer.

[25]  D. Alberts,et al.  Simple numeric abnormalities as primary karyotype changes in ovarian carcinoma , 1994, Genes, chromosomes & cancer.

[26]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[27]  S. Nimer,et al.  Transcription factors, translocations, and leukemia , 1992 .

[28]  R. Chaganti,et al.  Genetic changes in epithelial solid neoplasia. , 1994, Cancer research.

[29]  D. Alberts,et al.  Clonal chromosome abnormalities in 54 cases of ovarian carcinoma. , 1994, Cancer genetics and cytogenetics.

[30]  D. Alberts,et al.  Band 1p36 abnormalities and t(1;17) in ovarian carcinoma. , 1997, Cancer genetics and cytogenetics.

[31]  R. J. Meador,et al.  Double minutes are frequently found in ovarian carcinomas. , 1993, Cancer genetics and cytogenetics.

[32]  Thomas Ried,et al.  Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping , 1997, Nature Genetics.

[33]  J. Testa Chromosome translocations in human cancer. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[34]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[35]  B. Johansson,et al.  Clinical significance of cytogenetic findings in solid tumors. , 1997, Cancer genetics and cytogenetics.

[36]  J. Rey,et al.  Chromosome aberrations in metastatic ovarian cancer: Relationship with abnormalities in primary tumors , 1990, International journal of cancer.

[37]  D. Alberts,et al.  Expression of the zinc finger gene EVI-1 in ovarian and other cancers. , 1996, British Journal of Cancer.

[38]  D. Alberts,et al.  Chromosome abnormalities in ovarian adenocarcinoma: II. prognostic impact of nonrandom chromosome abnormalities in 244 cases , 1999, Genes, chromosomes & cancer.

[39]  J. Trent,et al.  Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. , 1995, Cancer genetics and cytogenetics.

[40]  J. Whang‐Peng,et al.  Cytogenetic studies in ovarian cancer. , 1984, Cancer genetics and cytogenetics.

[41]  P. Sorensen,et al.  Gene fusions encoding chimaeric transcription factors in solid tumours. , 1996, Seminars in cancer biology.